Vimarsana
Biggest News Aggregation in the World

Page 13 - Eric Soyer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eric Soyer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eric Soyer Today - Breaking & Trending Today

ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of ... - Vimarsana News

ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of ... Erytech Pharma S.A.April 19, 2021 GMT ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer No dose-limiting toxicity reported in the first dose cohort Encouraging clinical activity observed in first patients Trial will be escalated to the next dose Lyon (France) and Cambridge, MA (U.S.), April 19, 2021 – ERYTECH Pharma (Nasd...

Source: apnews.com
ERYTECH to Host Fourth Quarter and Full Year 2020 Conference Call and Business Update - Vimarsana News

ERYTECH to Host Fourth Quarter and Full Year 2020 Conference Call and Business Update

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH to Host Fourth Quarter and Full Year 2020 Conference Call and Business Update Erytech Pharma S.A.March 4, 2021 GMT ERYTECH to Host Fourth Quarter and Full Year 2020 Conference Call and Business Update Lyon (France) and Cambridge, MA (U.S.), March 4, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its fourth qua...

Source: apnews.com
ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis - Vimarsana News

ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis Erytech Pharma S.A.February 8, 2021 GMT ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis                                                         The Independent Data Monitoring Committee (IDMC) recommends trial to continue to final analysis, expected in Q4 2021 No safety issues identified, consistent...

Source: apnews.com
ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference - Vimarsana News

ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Erytech Pharma S.A.January 6, 2021 GMT ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Lyon (France) and Cambridge, MA (U.S.), January 6, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced today that CEO, Gil Beyen, will present at the H.C....

Source: apnews.com
Investegate |Erytech Pharma S.A. Announcements | Erytech Pharma S.A.: ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer - Vimarsana News

Investegate |Erytech Pharma S.A. Announcements | Erytech Pharma S.A.: ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer A total of 510 patients enrolled Events required to trigger interim superiority analysis accrued Interim superiority analysis expected in Q1 2021; final analysis in Q4 2021 LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the completion of enrollment in the TRYbeCA-1 Phase 3 trial in ...